Anavex life sciences announces change of auditor to grant thornton llp

New york, march 04, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that it has changed its auditors from bdo usa llp (“bdo“) to grant thornton llp (“grant thornton“).
AVXL Ratings Summary
AVXL Quant Ranking